- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04842240
Comparison of Patient Reported Outcome Measures Using the BREAST-Q Questionnaire in Patients Undergoing Pre Versus Sub-pectoral Implant Based Immediate Breast Reconstruction. (PROM-Q)
Comparison of Patient Reported Outcome Measures in Patients Undergoing Pre Versus Sub-pectoral Implant Based Breast Reconstruction
The PROM Q study aims to compare patient reported outcome measures (PROMs) in patients undergoing mastectomy and immediate implant based breast reconstruction (IBR). This is the commonest form of breast reconstruction and current advances in surgical technology have led to increasing number of patients having implants placed above the pectoral muscle (pre-pectoral), rather than below it (sub-pectoral). This has important benefits for patients including shorter surgery time, quicker recovery, and avoidance of animation deformity (visible muscle twitching of the reconstructed breast) as the pectoral muscle is not divided to cover the implant. However, potential disadvantages include rippling effect as the implant is covered by the skin and subcutaneous tissue only, as well as potentially higher risk of capsule (scar tissue) formation.
By utilising a validated questionnaire (BREAST-Q), we will assess for any difference in PROMs between the two groups of patients. The results will provide valuable information for future patients when making an informed decision about their reconstruction options. This questionnaire study will include consecutive patients undergoing mastectomy and immediate IBR for breast cancer as well as for risk reduction at Leeds Teaching Hospitals NHS Trust. The study participants will undergo either pre- or sub-pectoral IBR based on their informed discussion with the clinical team. This is a non-randomised observational study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients who undergo implant based immediate breast reconstruction (IBR) are offered an option of pre- versus sub-pectoral breast reconstruction. Both approaches are well established and have proven safety in terms of low rate of complication rates. However, we do not know if there is a significant difference in patient reported outcome measures (PROMs) between the two surgical techniques over time.
The study aims to investigate if the difference in the surgical technique for immediate implant breast reconstruction (pre- versus sub-pectoral) influences patient perceived outcomes. This is a prospective non-randomised longitudinal cohort study which will aim to recruit consecutive eligible patients undergoing mastectomy with immediate implant based reconstruction surgery for early breast cancer or risk reduction using repeated measures and mixed methods.
This study will utilise a well validated patient questionnaire for breast reconstruction (BREAST-Q; http://qportfolio.org/breast-q/breast-cancer/) and will be carried out at a teaching hospital breast unit. The specific objectives will be to compare aesthetic outcome, post-operative pain and functionality as reported by PROMs. The study participants will be followed up for 12 months. The PROMs data will be collected at baseline, 2 weeks, as well as at 3 and 12 months post-surgery. Matching data will be collected for each study participant including the type of surgery performed, patient characteristics, post-operative complications, and any recommended adjuvant treatment. These data will be correlated with the matching questionnaire results in order to explore for potential clinical factors which may influence PROMs.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Baek Kim, FRCS MD MA
- Phone Number: 0113 2068724
- Email: b.kim@nhs.net
Study Contact Backup
- Name: Sue Hartup, RGN BSc PGC
- Phone Number: 0113 2068628
Study Locations
-
-
West Yorkshire
-
Leeds, West Yorkshire, United Kingdom, LS9 7TF
- Recruiting
- Leeds Teaching Hospitals NHS Trust
-
Contact:
- Baek Kim, FRCS MD MA
- Phone Number: 01132068724
- Email: B.Kim@nhs.net
-
Principal Investigator:
- Baek Kim, FRCS MD MA
-
Sub-Investigator:
- Shireen Mckenzie, FRCS(Ed) MD
-
Sub-Investigator:
- Sue Hartup, RGN BSc PGC
-
Sub-Investigator:
- Stacey Jones, MRCS(Ed) MBChB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Skin or nipple sparing mastectomy with immediate implant based reconstruction for breast cancer or for risk reduction
- Unilateral or bilateral mastectomy
- Implant or expander based immediate reconstruction
- Able to read and understand questionnaire in English
Exclusion Criteria:
- Male or transgender
- Mastectomy only with no reconstruction
- Delayed reconstruction
- Autologous reconstruction
- Cognitive impairment or inability to provide informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients undergoing implant based immediate breast reconstruction.
Patients will undergo either pre- or sub-pectoral implant based immediate breast reconstruction.
|
All study participants will undergo skin sparing mastectomy (with or without nipple preservation) for breast cancer or for risk reduction.
Patients will undergo immediate breast reconstruction using an implant or a tissue expander.
The device will be placed in pre- or sub-pectoral plane which will be supported by mesh (Tiloop/Surgimend Acellular Dermal Matrix) and/or a dermal flap.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To compare any difference in patient reported outcome measures in patients undergoing pre- versus sub-pectoral implant based breast reconstruction.
Time Frame: Up to 12 months post-surgery
|
To measure the difference in BREAST-Q score in patients undergoing pre- versus sub-pectoral implant based breast reconstruction.
We will compare psychosocial well-being, satisfaction with breasts, physical well-being, animation deformity, and patient experience with the clinical team.
|
Up to 12 months post-surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Baek Kim, FRCS MD MA, Leeds Teaching Hospitals NHS Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRAS 283017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on Pre- or sub-pectoral implant based immediate breast reconstruction
-
Tianjin Medical University Cancer Institute and...RecruitingBreast Cancer | Breast Reconstruction | Radiation | Synthetic MeshUnited States, China, Germany
-
IRCCS San RaffaeleEUBREAST ETSRecruitingBreast CancerSpain, United Kingdom, Italy, Turkey, Romania, Argentina, Egypt, Greece, Poland
-
University of OxfordNational Institute for Health Research, United KingdomEnrolling by invitationBreast Cancer | Risk ReductionUnited Kingdom
-
Ottawa Hospital Research InstituteRecruitingBreast Cancer | MastectomyCanada
-
Institut du Cancer de Montpellier - Val d'AurelleTerminated
-
Vastra Gotaland RegionRecruitingBreast Cancer | Weight Loss | Breast Reconstruction | Surgical Complication | Bariatric Surgery | Breast Implant Infection | Breast Implant | MastopexySweden
-
Tianjin Medical University Cancer Institute and...RecruitingImplant Breast Reconstruction | TiLOOP® Bra Mesh | Bovine Pericardial PatchChina
-
GCA (Eurosilicone)RecruitingBreast Reconstruction, Revision Breast Reconstruction | Breast Augmentation | Breast Reconstruction | Breast Revision-Augmentation | Breast Reconstruction With Silicone Implants | Breast Augmentation and Breast ReconstructionFrance, Spain
-
University in Zielona GóraConvaTec Inc.UnknownBreast Cancer | Breast ReconstructionPoland
-
Vastra Gotaland RegionRecruiting